DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,676,277 | -27.3% | 6,753 | -52.3% | 0.08% | +47.1% |
| Q2 2023 | $2,306,940 | +207.9% | 14,158 | +62.1% | 0.05% | +54.5% |
| Q1 2023 | $749,318 | +52668.9% | 8,734 | -42.6% | 0.03% | -13.2% |
| Q4 2022 | $1,420 | -99.8% | 15,216 | +69.4% | 0.04% | +65.2% |
| Q3 2022 | $900,000 | +16.7% | 8,982 | +18.0% | 0.02% | -4.2% |
| Q2 2022 | $771,000 | -37.5% | 7,612 | -37.5% | 0.02% | +60.0% |
| Q1 2022 | $1,233,000 | -3.6% | 12,178 | +220.1% | 0.02% | -40.0% |
| Q4 2021 | $1,279,000 | +123.2% | 3,805 | +102.9% | 0.02% | +127.3% |
| Q3 2021 | $573,000 | +24.6% | 1,875 | +9.0% | 0.01% | +10.0% |
| Q2 2021 | $460,000 | -7.3% | 1,720 | -21.4% | 0.01% | 0.0% |
| Q1 2021 | $496,000 | -6.6% | 2,188 | -8.7% | 0.01% | -54.5% |
| Q4 2020 | $531,000 | +23.8% | 2,397 | +21.2% | 0.02% | -15.4% |
| Q3 2020 | $429,000 | +7.2% | 1,978 | -15.2% | 0.03% | -18.8% |
| Q2 2020 | $400,000 | +33.8% | 2,332 | +8.2% | 0.03% | +6.7% |
| Q1 2020 | $299,000 | -11.3% | 2,155 | -2.4% | 0.03% | +20.0% |
| Q4 2019 | $337,000 | -0.3% | 2,209 | -8.0% | 0.02% | +8.7% |
| Q3 2019 | $338,000 | +312.2% | 2,402 | +286.2% | 0.02% | +109.1% |
| Q1 2019 | $82,000 | -89.4% | 622 | -91.8% | 0.01% | -76.6% |
| Q4 2018 | $774,000 | -10.9% | 7,604 | -4.9% | 0.05% | +34.3% |
| Q3 2018 | $869,000 | -32.2% | 7,997 | -38.4% | 0.04% | -35.2% |
| Q2 2018 | $1,281,000 | -18.1% | 12,982 | -23.0% | 0.05% | -23.9% |
| Q1 2018 | $1,565,000 | 0.0% | 16,859 | 0.0% | 0.07% | 0.0% |
| Q4 2017 | $1,565,000 | -1.9% | 16,859 | -9.3% | 0.07% | +12.7% |
| Q3 2017 | $1,595,000 | +2.8% | 18,594 | +1.1% | 0.06% | -4.5% |
| Q2 2017 | $1,551,000 | -1.7% | 18,384 | -0.4% | 0.07% | -4.3% |
| Q1 2017 | $1,578,000 | +13.2% | 18,453 | +3.0% | 0.07% | +3.0% |
| Q4 2016 | $1,394,000 | +28.1% | 17,913 | +29.1% | 0.07% | +17.5% |
| Q3 2016 | $1,088,000 | -19.6% | 13,876 | +3.6% | 0.06% | -25.0% |
| Q2 2016 | $1,353,000 | +1550.0% | 13,392 | +2053.1% | 0.08% | +590.9% |
| Q1 2016 | $82,000 | -92.9% | 622 | -95.0% | 0.01% | -85.7% |
| Q4 2015 | $1,150,000 | – | 12,387 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |